Edition:
India

Health and Happiness (H&H) International Holdings Ltd (1112.HK)

1112.HK on Hong Kong Stock

47.65HKD
13 Nov 2018
Change (% chg)

HK$-0.50 (-1.04%)
Prev Close
HK$48.15
Open
HK$48.40
Day's High
HK$49.50
Day's Low
HK$47.35
Volume
1,085,649
Avg. Vol
1,150,551
52-wk High
HK$64.50
52-wk Low
HK$36.30

Summary

Name Age Since Current Position

Fei Luo

54 Executive Chairman of the Board, Chief Executive Officer

Yidong Wang

44 2018 Chief Financial Officer, Executive Director

Abel Benzakour

54 2017 Chief Operating Officer

Malard Patrice

64 2012 Chief Technology Officer, General Manager of the Technology Center of Biostime Health

Dingping Zhu

42 2015 General Manager - Project Department of "Baby Nutrition and Care"

Garnier Laetitia

37 2018 Chief Strategy Officer and Executive Director

Qizhang Zhang

34 2015 Director - Integrated Marketing Center of the Group

Oliver Horn

46 2017 Managing Director - Swisse

Charles Ravel

42 2017 Managing Director - BNC International division

Tak Yee Wong

2010 Joint Company Secretary

Wenyun Yang

34 2010 Joint Company Secretary

Yun Luo

57 2010 Non-Executive Director

Wenhui Zhang

53 2012 Non-Executive Director

Wai Fung Ngai

56 2010 Non-Executive Independent Director

Wee Seng Tan

62 2010 Non-Executive Independent Director

Baichun Xiao

70 2010 Non-Executive Independent Director

Biographies

Name Description

Fei Luo

Mr. Luo Fei is Executive Chairman of the Board, Chief Executive Officer of the Company. Mr. Luo was appointed as an executive Director on 30 April 2010, and is also a director of the Company’s subsidiaries Biostime International Investment Limited (“Biostime Investment”), Biostime Hong Kong Limited (“Biostime Hong Kong”), Parenting Power International Holdings Limited (“Parenting Power Holdings”), Parenting Power Investment Limited (“Parenting Power Investment”), Parenting Power Hong Kong Limited (“Parenting Power Hong Kong”), Mama100 International Holdings Limited (“Mama100 Holdings”), Mama100 International Investment Limited (“Mama100 Investment”), Mama100 Hong Kong Limited (“Mama100 Hong Kong”), BiosTime, Inc. (Guangzhou) (“Biostime Guangzhou”), BMcare Baby Products Inc. (Guangzhou) (“BMcare Guangzhou”), Biostime (Guangzhou) Education Management Inc. (“Biostime Education”), Guangzhou Hapai Information Technology Co., Ltd. (“Guangzhou Hapai”) and Adimil (Changsha) Nutrition Products Limited (“Changsha Adimil”). Mr. Luo was appointed as a director of the Company’s indirectly wholly-owned subsidiaries, namely, Biostime Healthy Australia Pty Ltd, Biostime Healthy Australia Holdings Pty Ltd, Biostime Healthy Australia Investment Pty Ltd, Swisse Wellness Group Pty Ltd, SWG Holdco Pty Ltd, S W International Pty Ltd, Swisse Wellness Pty Ltd. in September 2015, Swisse China Limited on 16 December 2015, Swisse Wellness (Guangzhou) Limited (“Swisse Guangzhou”) on 15 April 2016. Mr. Luo is also a director of Guangzhou Mama100 E-commerce Co., Limited (“Mama100 E-commerce”), a company controlled by the Group through a series of structure contracts. He is also the supervisor of the Company’s subsidiary Biostime (Guangzhou) Health Products Limited (“Biostime Health”).

Yidong Wang

Mr. Wang Yidong serves as Chief Financial Officer, Executive Director of the Company. Mr. Wang is the Chief Finance Officer of the Group and is in charge of the overall financial and accounting affairs as well as investor relations of the Group. He has nearly 20 years of experience in financial management, accounting and corporate finance. Prior to joining the Group, Mr. Wang was Corporate Vice President and Asia Pacific Chief Finance Officer of Henkel AG & Co. KGaA, a German consumer goods giant (‘‘Henkel’’), responsible for Henkel’s financial management, business and operation controlling as well as M&A-related tasks in 14 countries of Asia Pacific. Before that, he worked at Henkel’s headquarters in Germany as Global Director of Business Development and M&A for the adhesive business unit, and previously worked as Henkel’s Greater China Chief Finance Officer and Asia Pacific Treasurer. Mr. Wang had also taken various financial management and banking roles with LG.Philips and JPMorgan Investment Bank in Hong Kong and New York. He began his career with China’s Ministry of Commerce and participated in the negotiations for China’s entry into the World Trade Organization. Mr. Wang was awarded “China CFO of the Year” in 2011 by the judging committee affiliated to China’s Ministry of Finance and also awarded "Outstanding CFO of China" in 2016 by CFO Magazine. Mr. Wang holds a Master of Business Administration degree from New York University Stern School of Business and a Bachelor of Arts degree from China Foreign Affairs University. He is a member of the American Institute of Certified Public Accountants (the “AICPA”) and a member of the Association of Chartered Certified Accountants (the “ACCA”).

Abel Benzakour

Mr. Abel Benzakour is Chief Operating Officer of the Company. He is responsible for overall procurement, logistics, production, supply chain, as well as global information technology and business intelligence, global compliance and control. Mr. Abel Benzakour has approximately 30 years of experience in the Fashion industry, Chemical and textile manufacturing. From November 1990 to August 1991, he worked for Algotex S.A as a contracting manager in the field of the Fashion Industry. From August 1991 to February 1995, he was employed by Tecnox S.A member of Wittock Van Landeghem group, leader in technical military items, as a technical and production director and plant director. From February 1995 to December 2011, he worked for Levi Strauss & Co Europe. During this period, he served as various positions, including the head of sourcing & product developments, the senior director of product and technical development, the vice president of global product development and sourcing, manufacturing & operations. He also has worked as group chief supply chain officer and EVP for Vivarte group S.A, French leader in Fashion industry, with 20 brands & banners for the period from October 2012 to December 2015. From April 2016 till March 2017, he worked as Freelance consultant in the raw material optimization and raw material strategy for Gap inc., large American fashion group with four global brands. Mr. Abel Benzakour worked as consultant for Tunisian Federation of the industry, Tunisia 2020 breakthrough and the Trans Pacific Partnership projects. He obtained his Bachelor Degree in Experimental Sciences from University of Sciences in 1984 and graduated in Textile Chemical Engineering in 1987 from ESITT (Ecole Superieure Industrielle du Textile de Tournai – Belgium).

Malard Patrice

Dr. Patrice Malard is the Chief Technology Officer, General Manager of the Technology Center of Biostime Health of the Company. He is responsible for research and development, product quality control and regulatory compliance. He was the scientific consultant of Biostime Guangzhou from 1 March 2008 to 30 September 2010. Dr. Patrice has approximately 30 years of experience in the nutrition products industry. From October 1981 to March 1990, he worked for Gist Brocades SA as a science director in the field of industrial enzymes. From April 1990 to June 1991, he was employed by CPIAA SA, an agro-consulting group, as a manager. From June 1991 to November 1994, he was the strategy and development director of the French subsidiary of Pioneer Hi-Bred in agro-seeds. He also has worked as a director of Silab Sarl in cosmetic ingredients and sales and Business development director of Lallemand SAS Human Nutrition division for the period from February 1995 to October 2007. From March 2008 till now, he is the owner of Kloarys Développement Sarl and acted as the general manager. He obtained his Ph.D. in molecular and cellular Biology from Lille University of Science and Technology in 1981.

Dingping Zhu

Mr. Zhu Dingping is General Manager - Project Department of "Baby Nutrition and Care" of the Company. He was our senior sales director and was mainly responsible for the overall sales affairs. Prior to joining the Group, he had over 10 years of experience in the pharmaceutical industry mainly obtained from working for companies in this industry. He was with Guangdong Minglin Pharmaceutical Co., Ltd. as a regional sales manager from August 1996 to December 2006. Mr. Zhu received a certificate of graduation in pharmaceutical science from China Pharmaceutical University in July 2006 for completing the adult higher education courses. He also participated in several advanced trainings so as to improve his professional skills. For instance, in September 2004, he attended the executive training program jointly held by the Asia-Pacific Institute of Business of the Chinese University of Hong Kong and Nin Jion Medicine Mfy (HK) Ltd. He had also completed the Business Administration training courses of Lingnan (University) College, Sun Yat-Sen University and received the certificate of completion in February 2003. He obtained a certificate of pharmacist by the Professional Titles Reform Work Leading Group of Guangdong Drug Administration in March 2003. He has completed the China Europe International Business School CMO training course and received the certificate of completion in July 2014. He had completed the EMBA courses of Management School, Jinan University and obtained a master’s degree in December 2015. He is currently serve for the enterprise institute of Jinan University, act as a part time researcher.

Garnier Laetitia

Ms. Laetitia Garnier serves as Chief Strategy Officer and Executive Director of the Company. joined the Group in July 2010. She is currently the Chief Strategy Officer of the Group. Before that, she was the General Manager of the Group Strategy and International Business. She is mainly responsible for Group strategy, acquisitions and investments, Group integration and management of Group international operations and business development. Since October 2016, Mrs. Laetitia Garnier has also assumed the role of Managing Director of Swisse China. From December 2003 to August 2010, she worked for the French Trade Commission in South China and was mainly responsible for providing lobbying and support to French companies partnering, exporting and investing in China, especially in the field of consumer goods and health sectors. Prior to that, she also has interned with the United States Senate in Washington D.C. from January to June 2001, the Banque Populaire Group in Paris from July to September 2001 and the LVMH Group in Paris from September 2002 to March 2003. In July 2003, she obtained a master’s degree in business administration and corporate strategy from the Institute of Political Studies in Paris.

Qizhang Zhang

Mr. Zhang Qizhang is Director - Integrated Marketing Center of the Group Mr. Zhang was the director in charge of the marketing, Biostime Business Unit and assumed additional responsibility as Director of Corporate Innovation Marketing Center. Mr. Zhang obtained his bachelor’s degree in public management in Renmin University of China in June 2007. After graduation, he was employed by Procter & Gamble (China) Co., Ltd. as a brand manager at the marketing department until May 2014.

Oliver Horn

Mr. Oliver Horn is Managing Director - Swisse, a Subsidiary Company of the Company. Mr. Horn has 20 years of expertise in the FMCG, beauty care and luxury goods sectors, and is experienced in global marketing and regional business management. He is also the director of the Company’s subsidiaries Biostime Healthy Australia Pty Ltd, Biostime Healthy Australia Holdings Pty Ltd, Biostime Healthy Australia Investments Pty Ltd, Swisse Wellness Group Pty Ltd, SWG Holdco Pty Ltd, S W International Pty Ltd, Swisse Wellness Pty Ltd, SW Production Holdings Pty Ltd, SW Translink Packaging Pty Ltd, SWG (US) Inc., Swisse Wellness Inc., Swisse Wellness Pty Ltd, Swisse Wellness GmbH and Swisse Wellness (UK) Limited. Before joining Swisse, Mr. Oliver Horn was the Integration Director at Treasury Wine Estates, where he successfully led the integration of the Diageo wine business into the EMEA business. Preceding this, he was GM for Central Europe, Middle East & Africa and Latin America. Prior to Treasury Wine Estates, Mr. Horn was the Group Brand Manager and Direct Marketing Manager of L’Oreal Paris (UK), and a Corporate Accounts Manager at Deutsche Bank (Germany). Mr. Horn holds a Bachelor of Business Administration (with Honours) from Arnhem Business School.

Charles Ravel

Mr. Charles Ravel is Managing Director - BNC International division of the Company. Mr. Charles Ravel, joined the Group in June 2017. He is currently the Managing Director of BNC International division of the Group. Mr. Charles Ravel is running the Group subsidiaries across Europe and Asia outside China. He is also in charge of Global Marketing for the brands housed under the BNC division. Mr. Charles Ravel spent most of his career in FMCG sector in the US (close to 10 years) and in Asia. His career started in the consumer division of Total S.A. from 2000 occupying different Marketing and Sales positions mainly in the US. During that time, he also led a post-acquisition brand switch in Eastern Europe and subsequently managed operations for Total Oil consumer division in the UK. Post JARDEN Corp. buyout, he led Category Management & Business Development for the Baby Care Division in the US for several years. He was then appointed in 2012 to develop Baby Care out of Asia being based subsequently in Hong Kong and in Shanghai. He led Sourcing Operations, Business Development and ultimately the business units across Asia Pacific in NEWELL BRANDS from 2015 to 2017. While having a sales and marketing background, he has held positions on an international scale in a wide array of functions including Operations. Mr. Charles Ravel studied International Marketing at FHW Berlin in Germany after getting a Bachelor of Arts degree in Economics from Rennes Business School in France. He also holds an MBA from University of San Francisco obtained with BGS honors in 2005.

Tak Yee Wong

Ms. Wong Tak Yee is Joint Company Secretary of Biostime International Holdings Ltd. She is a director, Corporate Services of Tricor Services Limited (“Tricor”), a global professional services provider specializing in integrated business, corporate and investor services. Ms. Wong has over 25 years of experience in the corporate secretarial field and has been providing professional corporate services to Hong Kong listed companies as well as multinational, private and offshore companies. Ms. Wong is a Chartered Secretary and a Fellow of both the HKICS and The Institute of Chartered Secretaries and Administrators in the United Kingdom. Ms. Wong is a holder of the Practitioner’s Endorsement from the HKICS. (Note: The Company has engaged Tricor as external service provider and appointed Ms. Wong as the Company’s joint company secretary and authorised representative since 12 July 2010.)

Wenyun Yang

Ms. Yang Wenyun is Joint Company Secretary of Biostime International Holdings Ltd. Ms. Yang works as the Director of the Listing Affairs and Risk Management Department, mainly in charge of overall listing affairs, legal affairs, administrative affairs and internal audit of the Group. She is also the supervisor of the Company’s subsidiary Swisse Guangzhou. Ms. Yang started her professional career with the Group and has obtained substantial experience through corporate governance, risk management, administration, legal affairs, information security management, internal audit, public relations and human resources management over the past twelve years with the Group. From August 2005 to December 2008, she worked as an assistant of public affairs and was mainly responsible for the legal affairs and public relations of the Group. Concurrently, being an assistant to the general manager since November 2006, she was responsible for part of administrative affairs of the Group. From December 2008 to February 2010, she was promoted to be the legal manager of the Group and was responsible for the overall legal affairs and public relations. In February 2010, she assumed the responsibility of leading the risk control department. In January 2014, she was promoted from a senior manager to become the director of the department. From October 2015 to February 2017, Ms. Yang was temporarily responsible for human resources management as the director of Corporate Affairs and Human Resources Department. Ms. Yang obtained a bachelor’s degree in law from Sun Yat-Sen University in June 2005.

Yun Luo

Mr. Luo Yun is Non-Executive Director of Biostime International Holdings Ltd. Mr. Luo was appointed as a non-executive Director on 12 May 2010, and is also a director of the Company’s subsidiaries Biostime Guangzhou, Biostime Health, BMcare Guangzhou, Biostime Education, Biostime Investment, Biostime Hong Kong, Parenting Power Holdings, Parenting Power Investment, Parenting Power Hong Kong, Mama100 Holdings, Mama100 Investment, Mama100 Hong Kong and Guangzhou Hapai. Mr. Luo is also a director of the Company’s substantial shareholder Biostime Pharmaceuticals with discloseable interests in the shares of the Company under the Provisions of Divisions 2 & 3 of Part XV of the SFO. For further details, please refer to page 64 of this Annual Report. From 1980 to 1993, Mr. Luo was employed by Haikou Qiongshan Medical Co., Ltd. Mr. Luo was employed as a sales manager for Guangzhou Biohope from December 1994 to August 1999. From August 1999 to September 2009, Mr. Luo held various positions in Biostime Guangzhou including the sales director and the director in charge of the Mama100 membership center. From September 2009 to December 2011, Mr. Luo was the general manager and director of a company formerly known as Biostime Health and Nutrition (Guangzhou) Limited (now known as Leseil Health and Nutrition (Guangzhou) Limited), where he was responsible for the overall strategies and business development. Mr. Luo graduated from Continuing Education School of Jinan University in July 1987 with a certificate of graduation in business and economic management. Mr. Luo has also completed the EMBA course at Fudan University in Shanghai and was awarded an EMBA degree in July 2012. Mr. Luo is the elder brother of Mr. Luo Fei, the Chairman of the Board and one of the Company’s executive Directors.

Wenhui Zhang

Dr. Zhang Wenhui serves as Non-Executive Director of the Company. Dr. Zhang was re-designated to a non-executive Director on 25 June 2012. Dr. Zhang was previously an executive Director of the Company from 12 May 2010 to 24 June 2012. Dr. Zhang is also a director of the Company’s substantial shareholder Biostime Pharmaceuticals with discloseable interests in the shares of the Company under the Provisions of Divisions 2 & 3 of Part XV of the SFO. For further details, please refer to page 64 of this Annual Report. Dr. Zhang has also been an independent director of Stoltze Specialty Processing, LLC in the United States since September 2012. Dr. Zhang has almost 18 years of experience in the biotechnology industry, through teaching in universities and working for several biotechnology companies. Dr. Zhang was a lecturer of bioengineering at South China University of Technology from August 1994 to August 1996. From December 2000 to August 2003, Dr. Zhang was employed as an assistant research professor in the department of chemical engineering in University of Nebraska-Lincoln in the United States. After that, Dr. Zhang was employed as a scientist in the process development department of Xoma (US) LLC in the United States from September 2003 to September 2005. Dr. Zhang joined the Group in October 2005 as the chief technology officer of Biostime Guangzhou and became a general manager of the technology center of Biostime Health in December 2010, where he was primarily responsible for the research and development, product quality control and technology support, and held this position until 24 June 2012. Dr. Zhang was also the chief technology officer and head of the Quality Assurance Department of the Company until 24 June 2012 and a director of the Company’s subsidiaries Biostime Guangzhou, Biostime Health and BMcare Guangzhou until 2 September 2012. Dr. Zhang received a bachelor’s degree in biochemical engineering from East China University of Science and Technology.

Wai Fung Ngai

Dr. Ngai Wai Fung, CPA, serves as Non-Executive Independent Director of Biostime International Holdings Ltd. Dr. Ngai was appointed as an independent non-executive Director on 12 July 2010 and is the chairman of the Audit Committee of the Company. Dr. Ngai is the managing director of MNCOR Consulting Limited and the chief executive officer of SW Corporate Services Group Limited, a specialty company secretarial corporate governance and compliance services provider to cmpanies in pre-IPO and post-IPO stages. Prior to that, he was the director and head of listing services of an independent integrated corporate services provider. He has over 20 years of senior management experience including acting as the executive director, chief financial officer and company secretary, most of which are in the areas of finance, accounting, internal control and regulatory compliance, corporate governance and secretarial work for listed issuers including major red chips companies. He had led or participated in a number of significant corporate finance projects including listings, mergers and acquisitions as well as issuance of debt securities. Dr. Ngai is the Past President of the Hong Kong Institute of Chartered Secretaries (the “HKICS”) and the Adjunct Professor of Law of Hong Kong Shue Yan University. Dr. Ngai was an independent non-executive director of China Railway Construction Corporation Limited from November 2007 to October 2014 and independent director of Sany Heavy Equipment International Holdings Company Limited from November 2009 to December 2015. Dr. Ngai is a fellow of the Association of Chartered Certified Accountants in the United Kingdom, a member of the Hong Kong Institute of Certified Public Accountants, a fellow of the Institute of Chartered Secretaries and Administrators, a fellow of the HKICS, a fellow of Hong Kong Institute of Directors and a member of Hong Kong Securities and Investment Institute. Dr. Ngai obtained a doctorate in Economics (Finance) at Shanghai University of Finance and Economics in 2011.

Wee Seng Tan

Mr. Tan Wee Seng is Non-Executive Independent Director of Biostime International Holdings Ltd. Company. Mr. Tan was appointed as an independent non-executive Director on 12 July 2010 and is the chairman of the Company’s Remuneration Committee. Mr. Tan is also an independent non-executive director of Xtep International Holdings Limited (Stock Code: 1368), an independent non-executive director and chairman of the audit committee of Sa\Sa International Holdings Limited (Stock Code: 178), an independent non-executive director and chairman of the audit committee of CIFI Holdings (Group) Company Limited (Stock Code: 884), an independent non-executive director and chairman of the audit committee of Sinopharm Group Company Limited (Stock Code: 1099), the shares of all of which are listed on the Main Board of the Stock Exchange. In addition, Mr. Tan is an independent director and, with effect from 8 March 2016, chairman of the audit committee of Renesola Ltd (Stock Code: SOL), the shares of which are listed on the NYSE. Mr. Tan is also a board member of Beijing City International School, an academic institution in Beijing. From November 2016, he ceased to be chairman of the finance committee of Beijing City International School. Mr. Tan has been appointed as an independent director and chairman of the audit committee of 7 Days Group Holdings Limited listed on the NYSE between November 2009 and July 2013 until it was privatized. He was the chairman of the special committee for the privatization of 7 Days Group Holdings Limited from October 2012 to July 2013. Mr. Tan has over 30 years of financial management, corporate finance, merger and acquisition, business management and strategy development experience. Mr. Tan has held various management and senior management positions in a number of multi-national corporations.

Baichun Xiao

Prof. Xiao Baichun is Non-Executive Independent Director of Biostime International Holdings Ltd. Prof. Xiao is a professional and scholar in management science. Professor Xiao has strong academic background and extensive experience in business management, which is relevant to the business operations of the Company in matters relating to corporate governance practices. From September 1990, he was with Seton Hall University as an assistant professor and was promoted to associate professor with tenure in April 1994 and to professor in March 1999. He was also the chairman of computing and decision sciences department of Seton Hall University from 1995 to 1997. Since September 1998, he has been with Long Island University pursuing his teaching career and is now a senior professor. He has also been the chairman of the department of management of Long Island University since 2003. Professor Xiao was appointed by various universities in China as either a chair professor or a visiting professor. Professor Xiao received a bachelor’s degree in mathematics from Nanjing University in July 1982, a MBA degree from Catholic University of Leuven, Belgium in March 1985, and his Ph.D. from Wharton School, University of Pennsylvania in December 1990.